News:

On July 2, 2010, as a result of a short-form merger under Delaware law, Javelin Pharmaceuticals became a wholly owned subsidiary of Hospira, Inc.  The historical information provided in this portion of the Javelin website is available over the short term for your convenience.

Javelin shareholders with share-related questions may refer to Hospira’s website at www.hospirainvestor.com or contact Hospira Investor Relations at:  www.hospira.com/GlobalPages/contactus.aspx.

July 1, 2010
Javelin Pharmaceuticals, Inc. Announces Successful Completion of Tender Offer for Its Common Stock by Hospira, Inc.